In 2015, AstraZeneca Pharma India was a $77 million subsidiary of a Anglo-Swedish multinational, running a single factory in Bengaluru and selling cardiovascular drugs that were losing patent protection. Ten years later, it crossed $206 million , nearly tripling revenue by betting everything on oncology. No acquisitions. No new factories. Just a portfolio pivot executed with unusual discipline.
Most pharmaceutical growth stories in India involve acquisition sprees, manufacturing scale-outs, or the slow grind of generic launches into Western markets. AstraZeneca India did none of these things. It tripled revenue from $76.7 million in FY15 to $206 million in FY25 using a single manufacturing facility on Bellary Road in Bengaluru, a workforce that actually shrank from 1,654 to around 1,400 employees, and a strategic decision to abandon the therapeutic categories that had built the company.
The trajectory was not linear. Revenue dipped to $81 million in FY18 as older cardiovascular franchises , Crestor, Seloken , lost ground to generic competition and Indian drug-pricing controls squeezed margins. The Bengaluru plant, while LEED Gold certified and WHO-cGMP compliant, was designed for an era when AstraZeneca India was primarily a tablet manufacturer. The question facing the India management team was whether a subsidiary that had spent decades distributing its parent’s older drugs could pivot to distributing its parent’s newest ones.
The answer arrived in the form of oncology molecules. Starting in FY19, revenue began climbing: $99.9 million, then $112.3 million, then a slight Covid-era dip to $110.7 million before the curve bent sharply upward , $130.9 million in FY23, $159.6 million in FY24, and $206 million in FY25. That final year represented 32% year-on-year growth, the highest rate among OPPI member companies in India. The company crossed the $200 million mark for the first time, recording revenue of 1,716 crore.
The strategic logic was straightforward, even if the execution was not. AstraZeneca PLC had spent the 2010s rebuilding itself as an oncology company , a transformation led by CEO Pascal Soriot that turned a patent-cliff-battered enterprise into one of the world’s largest cancer drug developers, with global revenue reaching $54.1 billion and R&D spend of $13.6 billion by 2024. The India subsidiary’s job was to bring those molecules to the Indian market before competitors could establish biosimilar or generic alternatives.
The pivot showed up first in the growth rates. In FY2020-21, AstraZeneca India became the fastest-growing oncology player in the country, with 150% growth in its cancer portfolio. It held the third-largest oncology brand position. That same year, the parent secured 10 major global regulatory approvals and the India entity obtained 17 clinical trial approvals from Indian regulators , a signal that the pipeline was being actively localized, not just passively received.
By FY2021-22, oncology was growing at 49.3% year on year, respiratory at 81.9%, and the company received three new medicine approvals and two new indication approvals in India. The following year, FY2022-23, oncology grew another 48%, respiratory 52%, and the cardiovascular-renal-metabolic segment added 18%. The compound effect of growing three therapeutic areas simultaneously at double-digit rates is what produced the tripling.
The pipeline acceleration that began in 2023 deserves its own accounting, because it represents something different from what AstraZeneca India had done before. Fourteen new medicine and indication approvals in roughly two years is not the behavior of a subsidiary that imports finished products and sells them. It is the behavior of a subsidiary that is actively integrating into its parent’s global launch cadence.
Consider the molecules involved. Tagrisso (osimertinib), the EGFR-mutant non-small-cell lung cancer treatment that generates $6.58 billion globally, is now available in India across multiple indications. Imfinzi (durvalumab), the PD-L1 checkpoint inhibitor, has moved beyond its initial biliary tract cancer approval into broader oncology use. Lynparza (olaparib), the PARP inhibitor developed in partnership with MSD, addresses BRCA-mutated breast and ovarian cancers. Calquence (acalabrutinib) treats chronic lymphocytic leukaemia. Enhertu (trastuzumab deruxtecan), the antibody-drug conjugate developed with Daiichi Sankyo, represents the cutting edge of targeted oncology.
Beyond oncology, Farxiga (dapagliflozin) , the SGLT2 inhibitor that generates $7.66 billion globally , has expanded from diabetes into heart failure and chronic kidney disease in India. Fasenra (benralizumab) addresses severe eosinophilic asthma. Koselugo (selumetinib) treats neurofibromatosis type 1, a rare disease with limited treatment options. The breadth of the portfolio tells you that AstraZeneca is no longer treating India as a market for its older drugs; it is treating India as a launch market for its best ones.
Patent filings are the closest thing to a forward indicator that the pharmaceutical industry produces. A company files patents years before it expects to commercialize a molecule in a given market. So when AstraZeneca’s India patent filings dropped from 247 in 2008 to just 3 in 2015, it was not a bureaucratic oversight , it was a signal that the parent company had deprioritized India as a market for its newest intellectual property.
The resurgence is equally telling. From that trough of 3 filings in 2015, activity crept back: 7 in 2016, 7 in 2017, 9 in 2018. Then, starting in 2022, the curve bent sharply upward , 11 filings, then 12, then 30 in 2024 and 28 in 2025. The first half of 2026 has already produced 8. Over the full timeline, AstraZeneca has made 1,228 patent filings in India, of which 67 have been granted.
The pattern tells a story in three acts. The first, from 2000 to 2008, was the era of aggressive IP protection , AstraZeneca was filing broadly to establish patent positions across its cardiovascular and gastrointestinal portfolio. The second, from 2009 to 2021, was the retreat , India’s Section 3(d) patent law, compulsory licensing debates, and drug-pricing controls made the country a less attractive market for patent-dependent innovation. The third act, from 2022 onward, is the return , driven by oncology molecules that command premium pricing even in India, and by a subsidiary that has demonstrated it can grow at 30% per year.
AstraZeneca India operates a single manufacturing facility , the LEED Gold certified plant on Bellary Road in Bengaluru, built to WHO-cGMP standards. In an industry where competitors like Sun Pharma operate forty plants and Cipla runs thirty-four, AstraZeneca’s single-site model is a deliberate choice, not a limitation. The Bengaluru facility produces tablets and formulations for the domestic market while the parent’s global network handles the biologics and injectables that require specialized manufacturing.
The lean manufacturing footprint means that AstraZeneca India’s growth has come almost entirely from portfolio mix and commercial execution rather than capacity expansion. Revenue per employee has risen from roughly $46,000 in FY15 to over $147,000 in FY25 , a threefold improvement that mirrors the revenue tripling itself. With 1,400 employees generating $206 million, the India entity is among the most capital-efficient pharmaceutical operations in the country.
AstraZeneca PLC, headquartered in Cambridge with roots in both the United Kingdom and Sweden, recorded $54.1 billion in global revenue in 2024, spent $13.6 billion on research and development, and generated $7.0 billion in net income. The India subsidiary’s $206 million represents less than 0.4% of the parent’s revenue , yet the growth rate of the India entity, at 32%, exceeds the parent’s own growth. India is not yet material to AstraZeneca’s global numbers, but the trajectory suggests it will become so.
The parent has been operating in India since 1979 , forty-five years. It is listed on the BSE. The relationship between a multinational parent and its Indian subsidiary is always a negotiation: how much of the global pipeline gets localized, how much pricing flexibility the local team gets, how much the subsidiary is a distribution channel versus a genuine market participant. The patent resurgence and approval acceleration suggest that the negotiation has tilted decisively toward India in recent years.
Sources: AstraZeneca Pharma India Annual Reports FY2014–15 through FY2024–25. AstraZeneca PLC Annual Report 2024. Indian Patent Office. BSE India. OPPI.